Nasal spray could potentially treat COVID-19, NIH says - FOX 10 News Phoenix
An experimental drug to treat COVID-19, which can be taken orally, is now being tested in humans after showing early promise and effectiveness in hamsters.
The nasal spray contains COVID-19 antibodies that enter through primary sites of infection like the nasal cavities, making it harder for the virus to enter these areas and infect the rest of the body. .Earlier this month, NIH researchers say they identified a drug, TEMPOL, as a promising oral antiviral drug that can potentially limit SARS-CoV-2, the disease that causes COVID-19, by impairing the disease’s viral enzyme otherwise known as the RNA replicate. .Food and Drug Administration approved remdesivir, an antiviral medication developed by Gilead Sciences, as a treatment for COVID-19 patients requiring hospitalization.
The drug was the first fully approved treatment in the United States for COVID-19.RELATED: Pfizer begins phase 1 study of oral COVID-19 treatment drugIn March, Pfizer began studying an oral antiviral drug with the hopes of treating COVID-19